摘要
目的探讨塞来昔布在鼻咽癌放疗中的临床应用效果。方法选取我院2011年3月-2013年3月就诊的鼻咽癌患者67例,利用随机数字表格法将患者分为观察组(35例)与对照组(32例),对照组采取放射治疗,观察组在对照组基础上加以塞来昔布治疗,比较两组临床疗效、不良反应及并发症情况,同时统计两组随访1年、3年生存率。结果观察组近期有效率91.4%,对照组近期有效率71.9%,两组有效率比较差异有统计学意义(P<0.05)。两组放射性皮炎、口腔黏膜等不良反应发生率比较差异无统计学意义(P>0.05)。观察组心血管事件、贫血发生率、1年生存率、3年生存率分别为11.4%、8.6%、85.7%、74.3%,较对照组的3.1%、0、81.3%、68.8%差异无统计学意义(P>0.05)。结论塞来昔布辅助放射治疗能有效增强鼻咽癌近期疗效(总缓解率),不增加放射性皮炎等不良反应,但塞来昔布可能增加患者心血管事件及贫血发生几率,且对患者1年、3年生存率无明显影响。
Objective To investigate the clinical applicability of celecoxib to radiotherapy of nasopharyngeal carcinoma.Methods A total of 67 patients with nasopharyngeal carcinoma were divided into the observation group（ 35 cases） and control group（ 32 cases） by random number table method.The control group was treated with radiotherapy.Besides radiotherapy,the observation group was also treated with celecoxib.The clinical curative effect,adverse reactions and complications were compared between the two groups.Moreover,the 1-year and 3-year survival rates of the two groups were statistically analyzed.Results The short-term effective rate of the observation group was 91.4% while that of the control group was 71.9%（ P〈0.05）.There was no significant difference in the incidence of adverse reactions,such as radiation dermatitis and oral mucosa,between the two groups（ P〉0.05）.The incidence of cardiovascular events and anemia,1-year and 3-year survival rates were 11.4%,8.6%,85.7% and74.3%,respectively,compared with 3.1%,0,81.3%,and 68.8% in the control group.There was no significant difference between the two groups（ P 〉 0.05）.Conclusion Celecoxib-assisted radiotherapy can effectively enhance the short-term curative effect（ total remission rate） of nasopharyngeal carcinoma without increasing the radiation dermatitis and other adverse reactions.However,celecoxib may increase the incidence of cardiovascular events and anemia.It has no obvious effect on the 1-year or 3-year survival rates.
出处
《解放军预防医学杂志》
CAS
2017年第7期780-782,共3页
Journal of Preventive Medicine of Chinese People's Liberation Army
基金
四川省卫生厅重点科技基金资助项目(No.120419)
关键词
塞来昔布
鼻咽癌
放射治疗
缓解率
心脑血管事件
celecoxib
nasopharyngeal carcinoma
radiotherapy
remission rate
cardiovascular events
